Health Ministry Bans High-Dose Oral Nimesulide Formulations

January 01, 2026

Centre Prohibits Oral Nimesulide Above 100 mg

In a decisive move to strengthen pharmaceutical safety, the Union Health Ministry has banned all oral formulations of Nimesulide exceeding 100 mg , with effect from December 31, 2025 . The prohibition follows scientific evaluation of potential health risks and reflects a precautionary regulatory approach amid the availability of safer alternatives for pain and fever management.

Basis of the Government Decision

The notification states that higher-dose oral Nimesulide poses a likely risk to human health , particularly due to concerns of liver toxicity . The decision was taken after consultations with the Drugs Technical Advisory Board (DTAB) , the country’s apex technical advisory body on drug-related matters. The ministry emphasised that patient safety must prevail where therapeutic benefit does not clearly outweigh potential harm.

Regulatory History and Safety Concerns

Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) that has remained controversial worldwide because of hepatotoxic effects. In India, its use has already been prohibited in children below 12 years of age and banned for veterinary applications . Over the years, regulators have gradually narrowed its indications, and the latest restriction on higher oral doses aligns with this risk-mitigation trajectory.

Market Impact and Industry Exposure

The Nimesulide market, including fixed-dose combinations, is estimated to be worth around ₹500 crore . Several major pharmaceutical companies manufacture Nimesulide-based products. However, industry analysts note that formulations above 100 mg have limited market presence , suggesting the ban will have minimal commercial disruption while removing residual safety risks.

Public Health Signal

Experts interpret the move as a strong signal that India’s drug regulators are prioritising public health over marginal therapeutic utility . By eliminating higher-strength formulations altogether, the government ensures uniform compliance and reinforces a safety-first pharmaceutical framework.